Bavarian Nordic A/S (BVNRY)
OTCMKTS: BVNRY · Delayed Price · USD
7.45
+0.24 (3.33%)
May 3, 2024, 3:59 PM EDT - Market closed
Bavarian Nordic Revenue
In the year 2023, Bavarian Nordic had annual revenue of 7.06B DKK with 123.99% growth. Revenue in the quarter ending December 31, 2023 was 2.45B DKK with 89.81% year-over-year growth.
Revenue (ttm)
7.06B DKK
Revenue Growth
+124.21%
P/S Ratio
1.71
Revenue / Employee
5,122,941 DKK
Employees
1,379
Market Cap
1.74B USD
Revenue Chart
* This company reports financials in DKK.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 7.06B | 3.91B | 123.99% |
Dec 31, 2022 | 3.15B | 1.25B | 66.02% |
Dec 31, 2021 | 1.90B | 45.49M | 2.46% |
Dec 31, 2020 | 1.85B | 1.19B | 179.61% |
Dec 31, 2019 | 662.49M | 161.87M | 32.33% |
Dec 31, 2018 | 500.62M | -869.53M | -63.46% |
Dec 31, 2017 | 1.37B | 363.41M | 36.10% |
Dec 31, 2016 | 1.01B | -13.82M | -1.35% |
Dec 31, 2015 | 1.02B | -196.25M | -16.13% |
Dec 31, 2014 | 1.22B | 4.31M | 0.36% |
Dec 31, 2013 | 1.21B | 195.87M | 19.27% |
Dec 31, 2012 | 1.02B | 493.04M | 94.16% |
Dec 31, 2011 | 523.60M | 209.53M | 66.71% |
Dec 31, 2010 | 314.07M | 239.29M | 319.98% |
Dec 31, 2009 | 74.78M | -134.02M | -64.19% |
Dec 31, 2008 | 208.81M | -123.30M | -37.13% |
Dec 31, 2007 | 332.10M | 156.81M | 89.46% |
Dec 31, 2006 | 175.29M | -72.30M | -29.20% |
Dec 31, 2005 | 247.60M | 82.81M | 50.26% |
Dec 31, 2004 | 164.78M | -339.86M | -67.35% |
Dec 31, 2003 | 504.64M | 383.57M | 316.79% |
Dec 31, 2002 | 121.08M | - | - |
Dec 31, 2001 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 371.62B |
Johnson & Johnson | 81.80B |
Merck & Co. | 60.12B |
AbbVie | 54.40B |
Novartis AG | 49.92B |
AstraZeneca | 47.61B |
Thermo Fisher | 42.49B |
Abbott Laboratories | 40.33B |
BVNRY News
- 6 days ago - Bavarian Nordic Receives 65 mEUR Contract to Supply Smallpox Vaccines for EU Strategic Reserve - GlobeNewsWire
- 6 days ago - Bavarian Nordic Initiates Rolling Submission of Biologics License Application with FDA for its Chikungunya Vaccine Candidate - GlobeNewsWire
- 13 days ago - Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such - GlobeNewsWire
- 19 days ago - Resolutions of the Annual General Meeting 2024 of Bavarian Nordic A/S - GlobeNewsWire
- 4 weeks ago - Morris & Dickson is the First U.S. Distributor for Bavarian Nordic's JYNNEOS®, the Only FDA-approved Mpox Vaccine - Business Wire
- 4 weeks ago - Bavarian Nordic Announces Commercial Launch of Mpox Vaccine in the U.S. - GlobeNewsWire
- 6 weeks ago - Bavarian Nordic A/S – Notice Convening Annual General Meeting - GlobeNewsWire
- 7 weeks ago - Bavarian Nordic Receives Approval of Smallpox and Mpox Vaccine in Switzerland - GlobeNewsWire